Kicking off a six-part series on peer review, ClinPharmPod host Alaina Webster chats with Dr. Sarah Holstein, Associate Professor at the University of Nebraska Medical Center and Associate Editor for Clinical Pharmacology & Therapeutics (CPT) about the importance of peer review in scientific research and what might constitute a conflict of interest for potential reviewers.
You can access CPT’s Reviewer Instructions here.
For this episode of ClinPharmPod, host Alaina Webster sits down with Dr. Don Willis, Assistant Professor at the University of Arkansas for Medical Sciences, and moderator Dr. Erica Woodahl, Professor at the University of Montana and Associate Editor for Clinical and Translational Science (CTS). They discuss Don and his colleagues’ recent publication in CTS, “COVID-19 vaccine hesitancy: Race/ethnicity, trust, and fear,” digging into how location, race, past racism, and current systemic racism factor into the willingness to receive a COVID-19 vaccination.
On the latest episode of PSPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.
On the latest episode of ClinPharmPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.
On this episode of PSPod, Dr. Rajanikanth Madabushi from the US Food and Drug Administration continues our recent discussion on model-informed drug development (MIDD) and its role in the successful implementation of PDUFA VI. This discussion is based on his co-authored Perspective article (with Drs. Yaning Wang and Issam Zineh) “A Holistic and Integrative Approach for Advancing Model‐Informed Drug Development” which published in the January 2019 issue of PSP. The article is available here.
